Analysts Set Humacyte, Inc. (NASDAQ:HUMA) Price Target at $6.25

Shares of Humacyte, Inc. (NASDAQ:HUMA) have received an average rating of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $6.1071.

Several brokerages have commented on HUMA. Benchmark lowered their price target on Humacyte from $2.00 to $1.00 and set a “speculative buy” rating on the stock in a report on Thursday. D. Boral Capital restated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research note on Tuesday, April 28th. Wall Street Zen downgraded shares of Humacyte from a “sell” rating to a “strong sell” rating in a report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research note on Wednesday, July 8th. Finally, TD Cowen lowered their target price on shares of Humacyte from $1.50 to $1.25 and set a “buy” rating on the stock in a research note on Wednesday, June 17th.

Insider Buying and Selling

In related news, CFO Dale A. Sander sold 45,887 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the transaction, the chief financial officer directly owned 267,213 shares in the company, valued at approximately $240,491.70. This represents a 14.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathleen Sebelius bought 56,818 shares of Humacyte stock in a transaction that occurred on Tuesday, May 19th. The stock was purchased at an average cost of $0.88 per share, with a total value of $49,999.84. Following the completion of the transaction, the director owned 148,025 shares of the company’s stock, valued at $130,262. This trade represents a 62.30% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 3.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Humacyte

Several institutional investors and hedge funds have recently bought and sold shares of the business. Ieq Capital LLC acquired a new position in shares of Humacyte in the 2nd quarter valued at $218,000. LaSalle St. Investment Advisors LLC acquired a new stake in shares of Humacyte during the 2nd quarter valued at about $89,000. BlackRock Inc. acquired a new stake in shares of Humacyte during the 2nd quarter valued at about $3,777,000. Wealth Effects LLC bought a new stake in Humacyte in the second quarter valued at about $542,000. Finally, Bank of New York Mellon Corp bought a new stake in Humacyte in the second quarter valued at about $44,000. Institutional investors own 44.71% of the company’s stock.

Key Humacyte News

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $4.00 price target for Humacyte. Its forecast still anticipates a shift to profitability, with projected positive EPS of $0.09 in fiscal 2029 and $0.31 in fiscal 2030, suggesting potential long-term upside if the company successfully commercializes its products.
• Neutral Sentiment: HC Wainwright’s updated estimates project continued losses through fiscal 2028, followed by profitability in 2029 and 2030. The firm now expects fiscal 2026 EPS of ($0.46), fiscal 2027 EPS of ($0.30), and fiscal 2028 EPS of ($0.07).
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across multiple periods, including Q3 2026 to ($0.10) from ($0.09), Q4 2026 to ($0.11) from ($0.09), fiscal 2026 to ($0.46) from ($0.37), and fiscal 2027 to ($0.30) from ($0.26). Longer-term estimates were also cut, with fiscal 2029 EPS lowered to $0.09 from $0.20 and fiscal 2030 EPS to $0.31 from $0.50. These revisions indicate expectations for slower financial improvement.
• Negative Sentiment: Humacyte’s latest quarterly results missed expectations: the company reported a loss of $0.16 per share versus the $0.11 consensus loss, while revenue of $0.41 million was well below the $1.04 million estimate. The substantial operating losses and limited revenue reinforce concerns about cash needs and the timing of commercialization.
• Negative Sentiment: Additional bearish coverage is weighing on investor confidence. Benchmark issued a pessimistic forecast for HUMA. Benchmark Issues Pessimistic Forecast for Humacyte Wall Street Zen also downgraded Humacyte to a Strong Sell rating. Humacyte Lowered to Strong Sell Rating by Wall Street Zen

Humacyte Stock Performance

HUMA opened at $0.60 on Tuesday. The company has a market cap of $163.08 million, a PE ratio of -1.23 and a beta of 2.53. The stock has a 50-day moving average of $0.78 and a 200-day moving average of $0.90. Humacyte has a 52-week low of $0.53 and a 52-week high of $2.55. The company has a debt-to-equity ratio of 2.07, a quick ratio of 3.32 and a current ratio of 6.21.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. The company had revenue of $0.41 million during the quarter, compared to the consensus estimate of $1.04 million. As a group, equities research analysts forecast that Humacyte will post -0.38 earnings per share for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.